GSK starts 2020 on a high, but warns of tougher times ahead

GSK takes fight to AZ/Merck & Co with first-line ovarian can...

The FDA has approved GlaxoSmithKline’s Zejula as first-line maintenance treatment for women with platinum-responsive ovarian cancer, competing against AstraZeneca and Merck & Co’s class

PARP & DNA Damage Response Inhibitors Summit 2020

PARP DNA Damage Response Summit DDR Synthetic Lethality

ESMO 2019 – new data could unlock bigger market for PARP inh...

AstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as first-l

As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian...

Relief for GSK as Tesaro’s Zejula hits the mark in ovarian c...